Cellular signaling in response to TGFβ: The paradox of a factor that blocks cell proliferation and enhances metastasis;Signalisation cellulaire en reponse au TGFβ: Le paradoxe d'une cytokine a la fois inhibitrice de la proliferation cellulaire et inductrice de metastases

Bulletin du Cancer

Volumn 86, Issue 11, 1999, Pages 903-910

  Vignais, Marie Luce ^a  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

Cancer; Metastases; Regulation of TGF signaling; SMAD proteins; Transforming growth factor

Indexed keywords

REGULATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; DNA BINDING PROTEIN; LIGAND; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CANCER; CELL PROLIFERATION; METASTASIS; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; CANCER INVASION; CELL DIVISION; EXTRACELLULAR MATRIX; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

CELL DIVISION; DNA-BINDING PROTEINS; EXTRACELLULAR MATRIX; LIGANDS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033228337     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Attisano L, Wrana JL. Mads and Smads in TGF beta signalling. Curr Opin Cell Biol 1998; 10: 188-94.
2. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998; 95: 737-40.
3. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-71.
4. Kawabata M, Miyazono K. Signal transduction of the TGF-beta superfamily by Smad proteins. J Biochem (Tokyo) 1999; 125: 9-16.
5. Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998; 8: 103-11.
6. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-91.
7. Whitman M. Smads and early developmental signaling by the TGF-beta superfamily. Genes Dev 1998; 12: 2445-62.
8. Luo K, Lodish HF. Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues. Embo J 1997; 16: 1970-81.
9. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-14.
10. Henis YI, Moustakas A, Lin HY, Lodish HF. The types II and III transforming growth factor-beta receptors form homo-oligomers. J Cell Biol 1994; 126: 139-54.
11. Weis-Garcia F, Massague J. Complementation between kinase-defective and activation-defective TGF-beta receptors reveals a novel form of receptor cooperativity essential for signaling. Embo J 1996; 15: 276-89.
12. Lawler S, Feng XH, Chen RH, Maruoka EM, Turck CW, Griswold Prenner I, et al. The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem 1997; 272: 14850-9.
13. Sekelsky J, Newfeld S, Raftery L, Chartoff E, Gelbart W. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 1995; 139: 1347-58.
14. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 1997; 272: 27678-85.
15. Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH. Phosphorylation of Ser465 and Ser467 in the C-terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 1997; 272: 28107-15
16. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, et al. Identification of Smad7, a TGF-beta-inducible antagonist of TGF-beta signalling. Nature 1997; 389: 631-5.
17. Imamura T, Takase M, Nishihara A, Oeda F, Hanai J, Kawabata M, Miyazono K. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997; 389: 622-6.
18. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998; 12: 186-97.
19. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad proteins exist as monomers in vivo and undergo homo- and heterooligomerization upon activation by serine/threonine kinase receptors. Embo J 1998; 17: 4056-65.
20. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998; 1: 611-7.
21. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 1998; 94: 585-94.
22. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. Embo J 1998; 17: 3091-100.
23. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the Jun B promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 1998; 273: 21145-52.
24. Vindevoghel L, Lechleider RJ, Kon A, de Caestecker MP, Uitto J, Roberts AB, Mauviel A. SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta. Proc Natl Acad Sci USA 1998; 95: 14769-74.
25. Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem 1999; 274: 8949-57.
26. Yingling JM, Datto MB, Wong C, Frederick JP, Liberati NT, Wang XF. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Mol Cell Biol 1997; 17: 7019-28.
27. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 1997; 389: 85-9.
28. Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev 1997; 11: 3157-67.
29. Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev 1998; 12: 2153-63.
30. Janknecht R, Wells NJ, Hunter T. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev 1998; 12: 2114-9.
31. Pouponnot C, Jayaraman L, Massague J. Physical and functional interaction of SMADs and p300/CBP. J Biol Chem 1998; 273: 22865-8.
32. Miyazono K, Hellman U, Wernstedt C, Heldin CH. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 1988; 263: 6407-15.
33. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-28.
34. Chen YG, Liu F, Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12. Embo J 1997; 16: 3866-76.
35. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 1996; 86: 435-44.
36. Huse M, Chen YG, Massague J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999; 96: 425-36.
37. Vignais ML. Protéines JAK et STAT dans la transmission du signal cellulaire. Med Sci 1997; 13: 1277-84.
38. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999; 397: 710-3.
39. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997; 389: 618-22.
40. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 1999; 13: 804-16.
41. Wotton D, Lo RS, Lee S, Massague J. A Smad transcriptional corepressor. Cell 1999; 97: 29-39.
42. Iseki S, Osumi-Yamashita N, Miyazono K, Franzen P, Ichijo H, Ohtani H, et al. Localization of transforming growth factor-beta type I and type II receptors in mouse development. Exp Cell Res 1995; 219: 339-47.
43. Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, et al. Determinants of specificity in TGF-beta signal transduction. Genes Dev 1998; 12: 2144-52.
44. Feng XH, Derynck R. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. Embo J 1997; 16: 3912-23.
45. Lo RS, Chen YG, Shi Y, Pavletich NP, Massague J. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-beta receptors. Embo J 1998; 17: 996-1005.
46. Wong C, Rougier-Chapman EM, Frederick JP, Datto MB, Liberati NT, Li JM, et al. Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta. Mol Cell Biol 1999; 19: 1821-30.
47. Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M, et al. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 1999; 284: 479-82.
48. Sirard C, de la Pompa L, Elia A, Itie A, Mirtsos C, Cheung A, et al. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev 1998; 12: 107-19.
49. Yang X, Li C, Xu X, Deng C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci USA 1998; 95: 3667-72.
50. Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX. Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the minor suppressor smad2. Proc Natl Acad Sci USA 1998; 95: 9378-83.
51. Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ. Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell 1998; 92: 797-808.
52. Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, Zwijsen A. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 1999; 126: 1631-42.
53. Vignais ML. Smad3 mice: a murine model for the study of human colorectal cancers? Bull Cancer 1998; 85: 989-90.
54. Zhu Y, Richardson JA, Parada LF, Graff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998; 94: 703-14.
55. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. Embo J 1999; 18: 1280-91.
56. Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 1996; 87: 1439-45.
57. Hata A, Lo RS, Wotton D, Lagna G, Massague J. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 1997; 388: 82-7.
58. Shi Y, Hata A, Lo RS, Massague J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997; 388: 87-93.
59. Amendt C, Schirmacher P, Weber H, Blessing M. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 1998; 17: 25-34.
60. Bottinger EP, Jakubczak JL, Roberts IS, Mumy M, Hemmati P, Bagnall K, et al. Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas. Embo J 1997; 16: 2621-33.
61. Chen RH, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science 1993; 260: 1335-8.
62. Huang F, Newman E, Theodorescu D, Kerbel RS, Friedman E. Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. Cell Growth Differ 1995; 6: 1635-42.
63. Sehgal I, Baley PA, Thompson TC. Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996; 56: 3359-65.
64. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, et al. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86: 531-42.
65. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-4.
66. Jeanteur P. Immunosuppresseurs et augmentation du risque de cancer. Bull Cancer 1999; 86: 333.